Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Thomas Burke, BPharm, MBA, President, Saint Francis Hospital & Mount Sinai Rehabilitation Hospital Phil Boiselle, M.D., Dean, Frank H. Netter, M.D. School of Medicine at Quinnipiac University Kwame Asante, M.D., Medical Director, Mount Sinai Rehabilitation Hospital Mary Bailey, M.D., Regional Medical Director, Rehabilitation and Multiple Sclerosis, Trinity Health Of New England Dr. DeLuca Syed Hussain, M.D., Chief Clinical Officer, Trinity Health Of New England

From left to right: Thomas Burke, BPharm, MBA, President, Saint Francis Hospital & Mount Sinai Rehabilitation Hospital, Phil Boiselle, M.D., Dean, Frank H. Netter, M.D. School of Medicine at Quinnipiac University, Kwame Asante, M.D., Medical Director, Mount Sinai Rehabilitation Hospital, Mary Bailey, M.D., Regional Medical Director, Rehabilitation and Multiple Sclerosis, Trinity Health Of New England, Dr DeLuca, Syed Hussain, M.D., Chief Clinical Officer, Trinity Health Of New England

Visitors from Oxford included Gabriele DeLuca, Professor of Clinical Neurology and Experimental Neuropathology. The group, which is looking to spearhead change within the NHS, looked at the comprehensive care model that the Mandell MS Center provides to patients. This comprehensive care model includes fellowship-trained neurologists to fight disease progression along with a customised approach to treatment, rehabilitation therapy, and support services.

'The Oxford-Quinnipiac partnership provides an exceptional opportunity to break down boundaries between clinical neurosciences and rehabilitation to deliver world-leading integrated clinical care, education, and research,' said Dr DeLuca. 'The complementary strengths of our institutions have already inspired medical students and nurtured cutting-edge research. The meeting of clinical leadership is an important step in making the provision of multidisciplinary patient-centred care across our centres a reality. In so doing, we hope to make a palpable difference for the better in people with neurological conditions, together.'

The Mandell MS Center provides focused care and supportive services for MS patients. This includes field-leading innovative MS research in partnership with Oxford and Quinnipiac. Through an exchange programme with both universities, researchers are able to conduct innovative academic studies, where teams learn and implement the newest care models as soon as they are available. Patients have the option to participate in cutting-edge studies in the same place they receive care. The partnerships between providers at the Mandell MS Centers and researchers at Oxford and Quinnipiac lead to early intervention and better quality of care sooner after diagnosis.

The exchange programme involves medical students from Oxford and Quinnipiac's Frank H. Netter, M.D. School of Medicine. Oxford medical students participate in a clinical rotation at Mount Sinai, the primary partner for Quinnipiac's Institute for Rehabilitation Medicine. They also spend time at the Netter School, joining Quinnipiac students in learning opportunities that focus on the foundations of neurologic care with the view of bringing this experiential knowledge to the UK to enhance clinical care. Quinnipiac medical students participate in a six-week programme that includes an intensive seminar series at Oxford and four weeks of clinical neurology at the John Radcliffe Hospital.

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Collaboration with the Nepal Public Health Foundation (NPHF) explores maternal health and epilepsy

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.